To view this email as a web page, click here.
Conference Coverage
 
 March 04, 2019
 
The 2019 AAD Annual Meeting is taking place now until Tuesday, March 5 in Washington, D.C. Visit our conference page for our news reports from the meeting.
 
JAK inhibitors must meet high standards
While this new class of medications still has a role in treating psoriasis, this physician says the standard for both their efficacy and safety is very high because of the existing, already very effective systemic therapies available today.
 
Oral Tyk2 inhibitor promising for psoriasis
With a crowded indication that includes 14 systemic agents, is there really room for tyrosine kinase 2 (Tyk2) inhibitors to treat for psoriasis? This physician thinks so.
 
Cantharidin solution passes phase three trials
Drug-device combination, VP-102, met all primary and secondary endpoints in the parallel Cantharidin Application in Molluscum Patients (CAMP)-1 and CAMP-2 trials. Read what’s next for Verrica’s molluscum contagiosum treatment.
 
For live updates from the meeting, be sure to follow us at @DermTimesNow on Twitter!
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.